Caixin
Apr 28, 2021 07:45 AM
BUSINESS & TECH

Vaccine Startup Clover Biopharma Files for Hong Kong IPO

What’s new: Clover Biopharmaceuticals, a Chinese biotech startup developing Covid-19 and other vaccines, filed for an initial public offering (IPO) in Hong Kong, joining a raft of vaccine makers seeking financing through a public flotation.

Chengdu-based Clover didn’t disclose the size of the offering. Goldman Sachs and China International Capital Corporation (CICC) will sponsor the listing.

Several Chinese Covid-19 vaccine developers recently signaled attempts to go public, including Beijing Advaccine Biotechnology Co. Ltd. and Suzhou Abogen Biosciences, Caixin learned.

The context: Clover has been developing a Covid-19 vaccine based on recombinant protein technology. The company said in February that it expected to initiate a global Phase 2/3 trial of its Covid-19 vaccine candidate in the first half of 2021 and started production planning for potentially hundreds of millions of vaccine doses this year.

Clover in February raised $230 million in Series C financing from a group of investors led by Singapore state fund Temasek and GL Ventures, brings its total capital raised in the past 12 months to more than $400 million.

Quick Takes are condensed versions of China-related stories for fast news you can use. To read the full story in Chinese, click here.

Contact reporter Han Wei (weihan@caixin.com) and editor Bob Simison (bobsimison@caixin.com)

Support quality journalism in China. Subscribe to Caixin Global starting at $0.99.

Follow the Chinese markets in real time with Caixin Global’s new stock database.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code